Breast cancer metastatic+1
Not recruitingStudy of BB-1701 for Patients with HER2-positive or HER2-low Metastatic Breast Cancer
Study of BB-1701 for Patients with HER2-positive or HER2-low Metastatic Breast Cancer
- Disease:Breast cancer metastaticHER2 positive breast cancer
- Substances:Humanised Igg1 Kappa Monoclonal Antibody Against Receptor Tyrosine-Protein Kinase Erbb-2 Conjugated To Eribulin
Spain- Participants:18–64 years · 65+ years
- Substances:Humanised Igg1 Kappa Monoclonal Antibody Against Receptor Tyrosine-Protein Kinase Erbb-2 Conjugated To Eribulin
- Sponsor:Eisai Limited











